Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • 1 in 10 young patients...

    1 in 10 young patients with MI will have familial hypercholesterolemia: JACC Study

    Written by Medha Baranwal Baranwal Published On 2019-05-20T20:28:28+05:30  |  Updated On 20 May 2019 8:28 PM IST
    1 in 10 young patients with MI will have familial hypercholesterolemia: JACC Study

    USA: Clinically defined familial hypercholesterolemia (FH) is prevalent in nearly 10% of young adults with myocardial infarction (MI), according to a recent study. Only two-thirds of FH patients were discharged on high-intensity statin therapy, and the vast majority had elevated LDL-C at 1 year.


    The findings, published in the Journal of the American College of Cardiology, reinforce the need for more aggressive lipid-lowering therapy in young FH and non-FH patients post-MI.


    Familial hypercholesterolemia is a common autosomal dominant disease caused by a defect on chromosome 19. This makes the removal of low-density lipoprotein (LDL, or bad) cholesterol from the blood difficult leading to an increased level of serum LDL cholesterol. FH increases the risk of coronary heart disease.


    There are limited data on the prevalence and treatment of familial hypercholesterolemia (FH) among U.S. adults who experience a myocardial infarction at a young age. Avinainder Singh, Brigham and Women’s Hospital, Boston, MA, and colleagues conducted this retrospective cohort study to evaluate the prevalence of clinically defined FH and examine the rates of statin utilization and LDL-C achieved 1-year post-MI.


    The YOUNG-MI registry included 1,996 adults with a median age of 45 years patients (19% were women, and 54% had ST-segment elevation MI) who experienced an MI at or below age 50 years between 2000 and 2016. Probable or definite FH was defined by the Dutch Lipid Clinic criteria. Outcomes included the proportion of patients classified as probable or definite FH, use of lipid-lowering therapy, and LDL-C achieved 1-year post MI.


    Also Read: Familial hypercholesterolemia does not increase risk of heart attack, finds study

    Key Findings:

    • Probable/definite FH was present in 180 (9%) of whom 42.8% were not on statins prior to their MI.

    • Of the 1,966 patients surviving until hospital discharge, 89.4% of FH patients and 89.9% of non-FH patients were discharged on statin therapy.

    • Among FH patients, 63.3% were discharged on high-intensity statin compared with 48.4% for non-FH patients.

    • At 1-year follow-up, the percent reduction in LDL-C among FH patients was −44.4% compared with −34.5% in non-FH patients.

    • The proportion of patients with LDL-C ≥70 mg/dl was higher among FH patients (82.2%) compared with non-FH patients (64.5%).


    Also Read: Medical Treatment of Familial Hypercholesterolemia

    "There was no difference in all-cause mortality in long-term follow-up between the FH and non-FH patients, adding that for this reason, it’s hard to justify add-on lipid-lowering therapy, such as ezetimibe or the PCSK9 inhibitors," editorialists write in an accompanying editorial. They, however, caution against drawing firm conclusions because the study was underpowered for fatal events in this relatively young patient population.


    For detailed study log on to DOI: 10.1016/j.jacc.2019.02.059
    cholesterolfamilial hypercholesterolemiaFHheart attack at young ageheart-attackJACCJournal of the American College of CardiologyLDL CLDL cholesterollipid lowering therapylow-density lipoproteinMImyocardial infarctionstatinStatin Therapyyoung adults
    Source : With inputs from Journal of the American College of Cardiology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok